142 exercise in chronic heart failure patients. J Am Coll Cardiol. 2001;37:1808–12. 72. Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski P, Poole-Wilson PA, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol. 1997;30:1758–64. 73. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60. 74. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001;50:2540–7. 75. Nagaya N, Uematsu M, Kosjima M, Date Y, Nakazato M, Okumura H, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure. Relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001;104:2034–8. 76. Cicoira M, Kalra P, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail. 2003;9:219–26. 77. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, Von Haehling S, Okonko DO, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005;46:1019–26. 78. Kopple JD. Pathophysiology of protein-energy wasting in chronic renal failure. J Nutr. 1999;129:247S–51S. 79. Kalanthar-Zadeh K, Balakrishan VS. The kidney disease wasting: inflammation, oxidative stress, and diet–gene interaction. Hemodial Int. 2006;10:315–25. 80. Nomenclature consensus conference: kidney disease wasting. In: Fouque D, Kalantar-Zadeh K, editors. Organizing the XIII International Congress on Metabolism and Nutrition in Renal Disease, Merida, Yucatan, Mexico; 2006. 81. Kalantar-Zadeh K, Block G, McAllister CJ, Humphries MH, Kopple JD. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr. 2004;80:299–307. 82. Campbell KL, MacLaughlin HL. Unintentional weight loss is an independent predictor of mortality in a hemodialysis population. J Ren Nutr. 2010;20:414–8. 83. Johansen KL. Anabolic and catabolic mechanisms in end-stage renal disease. Adv Chronic Kidney Dis. 2009;16:501–10. 84. Mitch WE. Proteolytic mechanisms, not malnutrition, cause loss of muscle mass in kidney failure. J Ren Nutr. 2006;16:208–11. 85. Siew ED, Pupim LB, Majchrzak KM, Shintani A, Flakoll PJ, Ikizler TA. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int. 2007;71:146–52. 86. Ikizler TA. Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease. J Ren Nutr. 2007;17:13–6. 87. Guarnieri G, Zanetti M, Vinci P, Cattin MR, Barazzoni R. Insulin resistance in chronic uremia. J Ren Nutr. 2009;19:20–4. J Cachexia Sarcopenia Muscle (2011) 2:135–142 88. Sandek A, Rauchhaus M, Anker SD, von Haehling S. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care. 2008;11:362–639. 89. Parks DA, Jacobson ED. Physiology of the splanchnic circula- tion. Arch Intern Med. 1985;145:1278–81. 90. Ding J, Cagnotti LJ, Huang Q, Xu DZ, Condon MR, Deitch EA. Hypoxia combined with Escherichia coli produces irreversible gut mucosal injury characterized by increased intestinal cytokine production and DNA degradation. Shock. 2001;16:189–95. 91. Ritz E. Intestinal–renal syndrome: mirage or reality? Blood Purif. 2011;31:70–6. 92. Mohi-ud-din K, Bali HK, Banerjee S, Sakhuja V, Jha V. Silent myocardial ischemia and high-grade ventricular arrhythmias in patients on maintenance hemodialysis. Ren Fail. 2005;27:171–5. 93. McIntyre CW. Haemodialysis-induced myocardial stunning in chronic kidney disease—a new aspect of cardiovascular disease. Blood Purif. 2010;29:105–10. 94. Wollert K, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6:95–103. 95. Ronco C, Cozzolino M. Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes. Heart Fail Rev. 2011. doi:10.1007/s10741-011-9232-8. 96. Kanzaki M, Soda K, Gin PT, Kai T, Konishi F, Kawakami M. Erythropoietin attenuates cachectic events and decreases produc- tion of interleukin-6, a cachexia-inducing cytokine. Cytokine. 2005;32:234–9. 97. Perez-Fontan M, Cordido F, Rodriguez-Carmona A, Peteiro J, Garcia-Naveiro R, Garcia-Buela J. Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2004;19:2095–100. 98. Yoshimoto A, Mori K, Sugawara A, et al. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol. 2002;13:2748–52. 99. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992–5. 100. Wu R, Dong W, Cui X, et al. Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg. 2007;245:480–6. 101. DeBoer MD, Zhu XX, Levasseur PR, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007;148:3004–12. 102. Baracos VE. Hypercatabolism and hypermetabolism in wasting states. Curr Opin Clin Nutr Metab Care. 2002;5:237–9. 103. Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflamma- tory cytokines in heart failure: double-edged swords. Heart Fail Rev. 2010;15:543–62. 104. von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8.